Browse PPP1R9B

Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Nucleus Cell projection, dendritic spine Cell junction, synapse. Cell junction, adherens junction Cytoplasm. Cell membrane. Cell projection, lamellipodium. Cell projection, filopodium. Cell projection, ruffle membrane. Note=Enriched at synapse and cadherin-based cell-cell adhesion sites. In neurons, both cytosolic and membrane-associated, and highly enriched in the postsynaptic density apposed to exitatory synapses. Colocalizes with PPP1R2 at actin-rich adherens junctions in epithelial cells and in dendritic spines (By similarity). Accumulates in the lamellipodium, filopodium and ruffle membrane in response to hepatocyte growth factor (HGF) treatment.
Domain PF00595 PDZ domain (Also known as DHR or GLGF)
Function

Seems to act as a scaffold protein in multiple signaling pathways. Modulates excitatory synaptic transmission and dendritic spine morphology. Binds to actin filaments (F-actin) and shows cross-linking activity. Binds along the sides of the F-actin. May play an important role in linking the actin cytoskeleton to the plasma membrane at the synaptic junction. Believed to target protein phosphatase 1/PP1 to dendritic spines, which are rich in F-actin, and regulates its specificity toward ion channels and other substrates, such as AMPA-type and NMDA-type glutamate receptors. Plays a role in regulation of G-protein coupled receptor signaling, including dopamine D2 receptors and alpha-adrenergic receptors. May establish a signaling complex for dopaminergic neurotransmission through D2 receptors by linking receptors downstream signaling molecules and the actin cytoskeleton. Binds to ADRA1B and RGS2 and mediates regulation of ADRA1B signaling. May confer to Rac signaling specificity by binding to both, RacGEFs and Rac effector proteins. Probably regulates p70 S6 kinase activity by forming a complex with TIAM1 (By similarity). Required for hepatocyte growth factor (HGF)-induced cell migration.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0001560 regulation of cell growth by extracellular stimulus
GO:0007015 actin filament organization
GO:0007050 cell cycle arrest
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007096 regulation of exit from mitosis
GO:0007346 regulation of mitotic cell cycle
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0008380 RNA splicing
GO:0009991 response to extracellular stimulus
GO:0010458 exit from mitosis
GO:0014072 response to isoquinoline alkaloid
GO:0016049 cell growth
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0030031 cell projection assembly
GO:0030308 negative regulation of cell growth
GO:0031668 cellular response to extracellular stimulus
GO:0038003 opioid receptor signaling pathway
GO:0043278 response to morphine
GO:0043279 response to alkaloid
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0045786 negative regulation of cell cycle
GO:0045926 negative regulation of growth
GO:0046847 filopodium assembly
GO:0050804 modulation of synaptic transmission
GO:0051783 regulation of nuclear division
GO:0071312 cellular response to alkaloid
GO:0071315 cellular response to morphine
GO:0071317 cellular response to isoquinoline alkaloid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071496 cellular response to external stimulus
GO:1901987 regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:2000474 regulation of opioid receptor signaling pathway
Molecular Function GO:0003779 actin binding
GO:0004857 enzyme inhibitor activity
GO:0004864 protein phosphatase inhibitor activity
GO:0008157 protein phosphatase 1 binding
GO:0019208 phosphatase regulator activity
GO:0019212 phosphatase inhibitor activity
GO:0019888 protein phosphatase regulator activity
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0051015 actin filament binding
Cellular Component GO:0000164 protein phosphatase type 1 complex
GO:0001726 ruffle
GO:0008287 protein serine/threonine phosphatase complex
GO:0014069 postsynaptic density
GO:0015629 actin cytoskeleton
GO:0030027 lamellipodium
GO:0030175 filopodium
GO:0030425 dendrite
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0032587 ruffle membrane
GO:0043197 dendritic spine
GO:0044309 neuron spine
GO:0060076 excitatory synapse
GO:0098794 postsynapse
GO:0098858 actin-based cell projection
GO:0099572 postsynaptic specialization
GO:1903293 phosphatase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPP1R9B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPP1R9B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPP1R9B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0350.906
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2030.928
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0910.958
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0770.829
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2150.931
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0970.976
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2180.569
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1510.928
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.260.892
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9450.549
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1950.611
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1140.0664
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPP1R9B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.8014.80.00448
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.8014.80.00826
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPP1R9B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPP1R9B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPP1R9B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPP1R9B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPP1R9B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPP1R9B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPP1R9B
Nameprotein phosphatase 1, regulatory subunit 9B
Aliases SPINO; spinophilin; Neurabin-2; PPP1R9; protein phosphatase 1, regulatory subunit 9B, spinophilin; protein p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPP1R9B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.